Entrada Therapeutics (TRDA) Operating Leases (2022 - 2026)
Entrada Therapeutics (TRDA) posted quarterly Operating Leases of $45.5 million for Q1 2026, down 9.94% year-over-year from $50.5 million in Q1 2025, and down 2.83% quarter-over-quarter from $46.8 million in Q4 2025.
Entrada Therapeutics (TRDA) Operating Leases (2022 - 2026) Analysis & Trends
Entrada Therapeutics' Operating Leases history runs 5 years deep, the most recent figure standing at $45.5 million for Q1 2026.
- In Q1 2026, Operating Leases fell 9.94% year-over-year to $45.5 million; the TTM figure through Mar 2026 stood at $45.5 million (down 9.94% YoY), while the FY2025 annual figure was $46.8 million, down 9.4% from the prior year.
- Operating Leases for Q1 2026 stood at $45.5 million, down from $46.8 million in the prior quarter.
- The five-year high for Operating Leases was $73.0 million in Q2 2023, with the low at $16.2 million in Q1 2023.
- The 5-year median for Operating Leases is $49.3 million (2025), against an average of $45.7 million.
- The sharpest annual moves came in 2023 and 2024: Operating Leases slumped 49.07% in 2023, then jumped 258.28% in 2024.
- Entrada Therapeutics' Operating Leases stood at $17.5 million in 2022, then jumped by 244.1% to $60.3 million in 2023, then dropped by 14.38% to $51.6 million in 2024, then dropped by 9.4% to $46.8 million in 2025, then declined by 2.83% to $45.5 million in 2026.
- Business Quant data shows TRDA's Operating Leases at $45.5 million in Q1 2026, $46.8 million in Q4 2025, and $48.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Entrada Therapeutics | 290.47 Mn | 290.47 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 44.10 Mn |
| Mar 31, 2026 | 45.47 Mn |
| Dec 31, 2025 | 46.79 Mn |
| Sep 30, 2025 | 48.05 Mn |
| Jun 30, 2025 | 49.28 Mn |
| Mar 31, 2025 | 50.49 Mn |
| Dec 31, 2024 | 51.65 Mn |
| Sep 30, 2024 | 53.58 Mn |
| Jun 30, 2024 | 55.88 Mn |
| Mar 31, 2024 | 58.13 Mn |
| Dec 31, 2023 | 60.32 Mn |
| Sep 30, 2023 | 69.07 Mn |
| Jun 30, 2023 | 73.03 Mn |
| Mar 31, 2023 | 16.23 Mn |
| Dec 31, 2022 | 17.53 Mn |
| Sep 30, 2022 | 27.95 Mn |
| Jun 30, 2022 | 21.80 Mn |
| Mar 31, 2022 | 31.86 Mn |